Terms: = Thyroid cancer AND BCL2, Bcl-2, 596, ENSG00000171791
463 results:
1. ANXA9 facilitates S100A4 and promotes breast cancer progression through modulating STAT3 pathway.
Zhou X; Zhao J; Yan T; Ye D; Wang Y; Zhou B; Liu D; Wang X; Zheng W; Zheng B; Qian F; Li Y; Li D; Fang L
Cell Death Dis; 2024 Apr; 15(4):260. PubMed ID: 38609357
[TBL] [Abstract] [Full Text] [Related]
2. Causal relationship of genetically predicted gut microbiota with thyroid cancer: a bidirectional two-sample mendelian randomization study.
Sun X; Chen S; Zhao S; Wang J; Cheng H
Front Endocrinol (Lausanne); 2024; 15():1284472. PubMed ID: 38495789
[TBL] [Abstract] [Full Text] [Related]
3. Carcinoma showing thymus-like elements (CASTLE) with amyloid deposition in the parotid gland.
Hamada M; Miyama Y; Matsumura S; Shintani-Domoto Y; Urano M; Yasuda M
Pathol Int; 2024 Apr; 74(4):227-233. PubMed ID: 38488752
[TBL] [Abstract] [Full Text] [Related]
4. Comprehensive Long-Read Sequencing Analysis Discloses the Transcriptome Features of Papillary thyroid Microcarcinoma.
Wang Y; Zou B; Zhang Y; Zhang J; Li S; Yu B; An Z; Li L; Cui S; Zhang Y; Yao J; Shi X; Liu J
J Clin Endocrinol Metab; 2024 Apr; 109(5):1263-1274. PubMed ID: 38038628
[TBL] [Abstract] [Full Text] [Related]
5. The m
Li P; Wang W; Zhou R; Ding Y; Li X
Clin Transl Med; 2023 Nov; 13(11):e1466. PubMed ID: 37983928
[TBL] [Abstract] [Full Text] [Related]
6. Systematic pharmacology-based strategy to explore the mechanism of Semen Strychni for treatment of papillary thyroid carcinoma.
Mao J; Tang L; Fang L; Tian C; Zhu Z; Li Y
Sci Rep; 2023 Oct; 13(1):18492. PubMed ID: 37898675
[TBL] [Abstract] [Full Text] [Related]
7. Exosome-Mediated lncRNA LINC01140 Attenuates Breast cancer Progression by Regulating the Wnt/β-Catenin Pathway.
Guo Z; Li Y; Li W; Li H; Wu Z
Crit Rev Eukaryot Gene Expr; 2023; 33(7):31-42. PubMed ID: 37602451
[TBL] [Abstract] [Full Text] [Related]
8. A specific RAGE-binding peptide inhibits triple negative breast cancer growth through blocking of Erk1/2/NF-κB pathway.
Dai X; Hou Y; Deng T; Lin G; Cao Y; Yu G; Wei W; Zheng Q; Huang L; Ma S
Eur J Pharmacol; 2023 Sep; 954():175861. PubMed ID: 37380046
[TBL] [Abstract] [Full Text] [Related]
9. Silencing of circUSPL1 represses breast cancer progression by targeting miR-1296-5p/MTA1 axis.
Wang P; Qu H; Wang L; Hu Z
Thorac Cancer; 2023 Aug; 14(22):2198-2209. PubMed ID: 37349877
[TBL] [Abstract] [Full Text] [Related]
10. Evaluation of the anticancer effect of telomerase inhibitor BIBR1532 in anaplastic thyroid cancer in terms of apoptosis, migration and cell cycle.
Turkmen E; Sogutlu F; Erdogan M; Biray Avci C
Med Oncol; 2023 Jun; 40(7):196. PubMed ID: 37284891
[TBL] [Abstract] [Full Text] [Related]
11. Expression Levels of MicroRNA-300/bcl2L11 in Papillary thyroid cancer and Their Clinical Diagnostic Values.
Shen Y; Li X; Xie R; Chen Y; Hu X; Liu Y; Ma H
Eur Surg Res; 2023; 64(3):342-351. PubMed ID: 37231813
[TBL] [Abstract] [Full Text] [Related]
12. Organoid models derived from patients with malignant phyllodes tumor of the breast.
Chu X; Wu M; Yang J; Fu Y; Wang X; Wang H; Xiao Y; Chen D; He J
Breast Cancer Res Treat; 2023 Jul; 200(2):193-201. PubMed ID: 37204665
[TBL] [Abstract] [Full Text] [Related]
13. Pharmacological updates of nifuroxazide: Promising preclinical effects and the underlying molecular mechanisms.
Althagafy HS; El-Aziz MKA; Ibrahim IM; Abd-Alhameed EK; Hassanein EHM
Eur J Pharmacol; 2023 Jul; 951():175776. PubMed ID: 37192715
[TBL] [Abstract] [Full Text] [Related]
14. Core Target and Key Signal Pathway of Xiaoluo in the Treatment of thyroid cancer.
Liang W; Zhang K; Sun Y; Chen L; Wang Z; Cheng W; Li W
Altern Ther Health Med; 2023 Jul; 29(5):400-409. PubMed ID: 37171951
[TBL] [Abstract] [Full Text] [Related]
15. YTHDC2 Retards Cell Proliferation and Triggers Apoptosis in Papillary thyroid cancer by Regulating CYLD-Mediated Inactivation of Akt Signaling.
Zhou G; Wang S
Appl Biochem Biotechnol; 2024 Jan; 196(1):588-603. PubMed ID: 37162682
[TBL] [Abstract] [Full Text] [Related]
16. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
[TBL] [Abstract] [Full Text] [Related]
17. Papillary thyroid carcinoma with aggressive fused follicular and solid growth pattern: A unique histological subtype with high-grade malignancy?
Murata SI; Matsuzaki I; Kishimoto M; Katsuki N; Onishi T; Hirokawa M; Kojima F
Pathol Int; 2023 May; 73(5):207-211. PubMed ID: 37042564
[TBL] [Abstract] [Full Text] [Related]
18. Combined treatment with
Huang S; Cui M; Wang R; Yang G; Wang N; Cui L; Ma G
Nucleosides Nucleotides Nucleic Acids; 2023; 42(9):731-742. PubMed ID: 36924446
[TBL] [Abstract] [Full Text] [Related]
19. Role of synaptotagmin 13 (SYT13) in promoting breast cancer and signaling pathways.
Zhang YD; Zhong R; Liu JQ; Sun ZX; Wang T; Liu JT
Clin Transl Oncol; 2023 Jun; 25(6):1629-1640. PubMed ID: 36630025
[TBL] [Abstract] [Full Text] [Related]
20. Downregulation of MDM2 by small interference RNA induces apoptosis and sensitizes MCF-7 breast cells to resveratrol.
Zhang NX; Ma JF; Li SQ; Yin Z; Li L
Chem Biol Drug Des; 2023 May; 101(5):1082-1088. PubMed ID: 36515454
[TBL] [Abstract] [Full Text] [Related]
[Next]
